Comparative Pharmacology
Head-to-head clinical analysis: CLENZ LYTE versus SUFLAVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLENZ LYTE versus SUFLAVE.
CLENZ-LYTE vs SUFLAVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colon lavage solution that osmotically induces diarrhea to cleanse the colon.
SUFLAVE is a combination of sulfamethoxazole, a sulfonamide antibiotic, and trimethoprim, a dihydrofolate reductase inhibitor. It inhibits bacterial folic acid synthesis by blocking two consecutive steps: sulfamethoxazole competes with PABA to inhibit dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
Oral: 4 L (or 240 mL every 10 minutes) administered the evening before colonoscopy; alternatively, 2 L (or 240 mL every 10 minutes) plus 2 L of clear liquids given in split doses (first 1-2 L evening before, remaining in morning of procedure).
250 mg intravenously every 12 hours.
None Documented
None Documented
Not applicable; systemic absorption is negligible (plasma levels below detection limits). Clinical effect is localized to gastrointestinal tract.
Terminal elimination half-life: 3.5 hours (range 2.5–4.5 h) in healthy adults; prolonged in renal impairment (up to 10 h in anuria)
Primarily fecal (approximately 95%) as unabsorbed polyethylene glycol; negligible renal excretion (<5%) as intact polymer.
Renal: 70% unchanged; fecal/biliary: 20%; 10% metabolized to inactive glucuronide
Category C
Category C
Laxative
Laxative